Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.

ABSTRACT:

Background

Personalized cancer vaccines based on neoantigens have reached the clinical trial stage in melanoma. Different vaccination protocols showed efficacy in preclinical models without a clear indication of the quality and the number of neoantigens required for an effective cancer vaccine.

Methods

In an effort to develop potent and efficacious neoantigen-based vaccines, we have developed different neoantigen minigene (NAM) vaccine vectors to determine the rules for a successful neoantigen cancer vaccine (NCV) delivered by plasmid DNA and electroporation. Immune responses were analyzed at the level of single neoantigen by flow cytometry and correlated with tumor growth. Adoptive T cell transfer, from HLA-2.1.1 mice, was used to demonstrate the efficacy of the NCV pipelin

SUBMITTER: Aurisicchio L 

PROVIDER: S-EPMC6376688 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature